Download Full Text (3.4 MB)


The standard form of treatment for locally advanced lung cancer is to prescribe the conventional dose of 60 Gy radiation therapy (RT) concurrently with chemotherapy. However, five-year overall survival is still less than 20%. These outcomes remain poor due to both distant and local regional recurrence. The literature suggests that local regional control and overall survival is strongly associated with doses of radiotherapy that are higher than 60 Gy. However, when escalating radiation dose was prescribed exceeding 70 Gy, the overall survival rates plateaued. The primary goal of this study is to determine if there is a marked difference in clinical outcomes (i.e., mortality, disease progression, local recurrence) when administering varying RT doses – standard 60 Gy vs. simulated integrated boost (SIB) to 70 Gy – in concordance with chemotherapy, to patients with locally advanced lung cancer. A secondary goal is to determine if our findings support of contradict the results of previous studies that examined escalating doses of radiotherapy.

Publication Date



Oncology | Radiation Medicine


The Embark Capstone Colloquium at the Oakland University William Beaumont School of Medicine, Rochester Hills, MI, May, 2023.

Outcomes of Locally Advanced Lung Cancer Patients Treated with 60 Gy vs. 70 Gy